Effect of Dapagliflozin, Compared With Placebo, According to Baseline Risk in DAPA-HF is a research paper published in JACC Heart Failure (2022). On theSindex it has a DataRank of 0.614. It has been cited 13 times, with 9 citing works in its 1-hop citation network.
Scored on demand from live citation data
Repositories this paper deposited data in (declared in PubMed).
DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?
FAIR checklist signals are shown for context only and do not affect DataRank scoring.
We only score data papers we can read in full — never from an abstract alone.
Base Score Contribution
0.396
From this paper's citation signal
Citation Network Contribution
0.218
From 7 citing papers with measurable signal
Ranked by each citer's contribution to N(p) — log1p(Cq) divided by its reference count — out of 9 citers.
British Heart Foundation
Grant: RE/18/6/34217
Bristol-Myers Squibb
MedImmune
National Institutes of Health
University of Glasgow
Cytokinetics
Daiichi-Sankyo
GlaxoSmithKline
Sanofi Pasteur
Janssen Research and Development
Respicardia
Abbott Laboratories
Bayer
Boehringer Ingelheim
IFM Therapeutics
National Heart, Lung, and Blood Institute
Novo Nordisk
Novartis
Eisai
Gilead UK and Ireland Corporate Contributions
Medicines Company
Pfizer
Actelion Pharmaceuticals
AstraZeneca
MyoKardia
Amgen
Merck
FWCI
1.50
Citation Percentile
0.8%
Citation Trend
Fields of Study
MeSH Terms
Keywords
Sustainable Development Goals